BIODOL TAB CAL-BONE ORTHODOL ADELA ADELA ADELA ADELA ADELA ADELA ALCAL OSTIBON CADLA BON-ONE HYPOCAL NENALFA NENALFA BONION BONION BONION INDROP ALPHA ALFADIX VITA BONE VITA BONE BONEDOL BONEDOL BONEDOL OSTEODOL ALFABONE ALFA-D ALFA-D ALFA-D ALFA-D ALFA-D ANIBONE BONCID RECALBON SERL ALPHA SERL ALPHA SERL ALPHA BONE LIFT BONAFIDE INJECTION ONE ALPHA ONE ALPHA ONE ALPHA ONE ALPHA ONE ALPHA XONE-ONE X-BONE X-BONE X-BONE BONREX BONREX ELSEDOL ELSEDOL ELSEDOL ERGOKET-D REBOOST REBOOST REBOOST REBOOST REBOOST REBOOST ENGBONE ENGBONE GROWELL TASOCAL BIOALFA UNI-DOL BIODOL CAP BIODOL BIOALFA BIO D3 DENS EVERALFA ALFADAL ALFADAL HIBONE ALFACAL EVER-ALFA EVER-ALFA ALCIDOL ALCIDOL ALCIDOL KELFA ALFADIN ALFADIN BONE-CARE OSCAL-D OSIVITOL BONEHEEL BONEHEEL HANCIDOL OSTEDOL ALFAMAK ALBONE D ALBONE D REBONE REBONE WINDOL WINDOL BON GROW BON GROW QUNJI PLUS TRYLOC TRYLOC TRYLOC CARACAL CARACAL A-BONE COLLAGIDOL VONE VONE BONIDOL BONIDOL BONIDOL BONIDOL BONEX ALFAGOOD MAXI-ALFA MAXI-ALFA MAXI-ALFA MAXI-ALFA MAXI-ALFA ALFACARE MEDCIDOL MEDCIDOL ALCIRON ALFAGEN ALFADOX FADOL ALCIDOL ALPHA-PLUS ALPHA-PLUS ALPHA-PLUS ALPHA-PLUS ALPHA-PLUS ALPHA-PLUS LINCAL MYALFA ALFASUN ALFAS CALSAF BONAFIDE TABS OSTEO-D VITALPHA-D UNIDOL ELCICAL ELCICAL ELCICAL ELCICAL HELPHA HELPHA NEXBONE NEXBONE

Dose: 0.25 to 1 mcg/kg
Single Dose: 0.62 (0.625)
Frequency: 24 hourly
Route: PO
Instructions: Maintenance

Dose: 0.05 mg/kg
Single Dose: 0.05 (0.05)
Frequency: 24 hourly
Route: oral
Instructions:

Dose: 0.05 ug/kg
Single Dose: 0.05 (0.05)
Frequency: 24 hourly
Route: Oral
Instructions: -

Alfacalcidol also known as Hydroxy Vit D3. . It is of Semi Synthetic origin and belongs to Hydroxycalciol. It belongs to Vitamin D agonist pharmacological group on the basis of mechanism of action. The Molecular Weight of Alfacalcidol is 400.60.

Alfacalcidol is contraindicated in conditions like Hypercalcaemia.

The severe or irreversible adverse effects of Alfacalcidol, which give rise to further complications include Hypercalciuria, Urinary calcium stone formation, Hypercalcemia, CNS depression.Alfacalcidol produces potentially life-threatening effects which include Coma. which are responsible for the discontinuation of Alfacalcidol therapy.The signs and symptoms that are produced after the acute overdosage of Alfacalcidol include Nausea, Vomiting, Diarrhea, Polyuria, Sweating, Headache, Anorexia, Vertigo, Thirst.

Alfacalcidol is primarily indicated in conditions like Neonatal hypocalcemia, Oncogenic hypophosphatemic osteomalacia, Osteomalacia in malabsorption syndrome, Osteoporosis, Parathyroid bone disease, Renal osteodystrophy, Renal tubular osteomalacia, Rickets in premature infants, Sporadic hypophosphatemic osteomalacia, Uremic osteodystrophy, Vitamin D therapy in patients with severe renal impairment, Vitamin D-dependent rickets, X-linked hypophosphataemic osteomalacia, and can also be given in adjunctive therapy as an alternative drug of choice in Psoriasis.

No data regarding the interactions of Alfacalcidol was found.

Interferes with assays for other plasma vitamin D metabolites

Drug should not be given to patients suffering from Kidney dysfunction, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Caps Store in a well closed container, Between 20°C-25°C. Inj Store Below 15°C.

Vitamin D should not be administered to patients with hypercalcaemia. Use with extreme caution in children, because they may have increase sensitivity to its effects and should be used with care in patients with renal impairment or calculi or heart disease. Plasma phosphate level should be controlled during vitamin D therapy. Use with caution during pregnancy.